Clinical Trials Begin to Treat Alpha-1 Liver Disease

TAP collaborator Arrowhead begins clinical trials on ARC-AAT to treat Alpha-1 liver disease. A groundbreaking trial of a potential treatment for Alpha-1-related liver disease has begun in Australia.Research poster design

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, on Monday announced it has started dosing in a Phase 1 clinical trial of ARC-AAT, the company’s candidate for treating Alpha-1-related liver disease.

Arrowhead partnered with The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, in June 2014 to develop treatment for Alpha-1 liver disease. Under the agreement, TAP will partially fund the development of ARC-AAT. In addition to the funding, TAP is making its scientific advisors available to Arrowhead, assisting with patient recruitment for clinical trials thanks to the Alpha-1 Foundation Patient Research Registry, and engaging in other collaborative efforts that support ARC-AAT development.

Source: Alpha-1 Foundation 23/02/2015